Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chronimed suspends Quick Check shipments:

This article was originally published in Clinica

Executive Summary

Chronimed has suspended all shipments of its Quick Check reagent strip in the US because of unresolved issues with its supplier, Diagnostic Solutions, and the FDA. Chronimed has started negotiations to acquire the manufacturing rights of the strip test from Diagnostic Solutions. The company, based in Minneapolis, Minnesota, must also resolve questions the FDA has about inconsistent strip test results before shipments can resume.

You may also be interested in...



Pfizer’s Expected 2020 COVID-19 Vaccine Production Fell By 50% After Scaleup Delays

Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.

Journey East: How Chinese Returnees Build Global-Bound Biopharmas

As Chinese returnees transform their startups to fully-fledged biopharma operations with a full product lineup and the global market in sight, the journey has been filled with challenges. Based on interviews and on-the-ground reporting, this new series takes a closer look at several companies' experiences.

US FDA Will Need About A Week To Complete COVID Vaccine Assessment Following Advisory Cmte., CBER’s Marks Says

Timeline is the most pessimistic public projection to date, but still incredibly fast. Clinical trial patients on placebo could be contacted and offered the vaccine after an EUA is granted.

Topics

UsernamePublicRestriction

Register

OM013133

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel